Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 47

1.

Cancer statistics, 2010.

Jemal A, Siegel R, Xu J, Ward E.

CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300. doi: 10.3322/caac.20073. Epub 2010 Jul 7. Erratum in: CA Cancer J Clin. 2011 Mar-Apr;61(2):133-4.

2.

Prostate apoptosis response protein 4 sensitizes human colon cancer cells to chemotherapeutic 5-FU through mediation of an NF kappaB and microRNA network.

Wang BD, Kline CL, Pastor DM, Olson TL, Frank B, Luu T, Sharma AK, Robertson G, Weirauch MT, Patierno SR, Stuart JM, Irby RB, Lee NH.

Mol Cancer. 2010 Apr 30;9:98. doi: 10.1186/1476-4598-9-98.

3.

Delivery of PAR-4 plasmid in vivo via nanoliposomes sensitizes colon tumor cells subcutaneously implanted into nude mice to 5-FU.

Kline CL, Shanmugavelandy SS, Kester M, Irby RB.

Cancer Biol Ther. 2009 Oct;8(19):1831-7.

PMID:
19729995
4.

The tumor suppressor Par-4 activates an extrinsic pathway for apoptosis.

Burikhanov R, Zhao Y, Goswami A, Qiu S, Schwarze SR, Rangnekar VM.

Cell. 2009 Jul 23;138(2):377-88. doi: 10.1016/j.cell.2009.05.022. Erratum in: Cell. 2009 Sep 4;138(5):1032.

5.

Targeting Akt3 signaling in malignant melanoma using isoselenocyanates.

Sharma A, Sharma AK, Madhunapantula SV, Desai D, Huh SJ, Mosca P, Amin S, Robertson GP.

Clin Cancer Res. 2009 Mar 1;15(5):1674-85. doi: 10.1158/1078-0432.CCR-08-2214. Epub 2009 Feb 10.

6.

Synthesis and anticancer activity comparison of phenylalkyl isoselenocyanates with corresponding naturally occurring and synthetic isothiocyanates.

Sharma AK, Sharma A, Desai D, Madhunapantula SV, Huh SJ, Robertson GP, Amin S.

J Med Chem. 2008 Dec 25;51(24):7820-6. doi: 10.1021/jm800993r.

7.

Par-4 inhibits Akt and suppresses Ras-induced lung tumorigenesis.

Joshi J, Fernandez-Marcos PJ, Galvez A, Amanchy R, Linares JF, Duran A, Pathrose P, Leitges M, CaƱamero M, Collado M, Salas C, Serrano M, Moscat J, Diaz-Meco MT.

EMBO J. 2008 Aug 20;27(16):2181-93. doi: 10.1038/emboj.2008.149. Epub 2008 Jul 24.

8.

Current overview of the role of Akt in cancer studies via applied immunohistochemistry.

Shtilbans V, Wu M, Burstein DE.

Ann Diagn Pathol. 2008 Apr;12(2):153-60. doi: 10.1016/j.anndiagpath.2007.12.001. Review.

PMID:
18325479
9.

The PI3K/Akt pathway and its downstream transcriptional factors as targets for chemoprevention.

Zhang X, Jin B, Huang C.

Curr Cancer Drug Targets. 2007 Jun;7(4):305-16. Review.

PMID:
17979625
10.

Downregulation of PAR-4, a pro-apoptotic gene, in pancreatic tumors harboring K-ras mutation.

Ahmed MM, Sheldon D, Fruitwala MA, Venkatasubbarao K, Lee EY, Gupta S, Wood C, Mohiuddin M, Strodel WE.

Int J Cancer. 2008 Jan 1;122(1):63-70.

11.

Protein expression and intracellular localization of prostate apoptosis response-4 (Par-4) are associated with apoptosis induction in nasopharyngeal carcinoma cell lines.

Lee JW, Lee KF, Hsu HY, Hsu LP, Shih WL, Chu YC, Hsiao WT, Liu PF.

Cancer Lett. 2007 Nov 18;257(2):252-62. Epub 2007 Sep 18.

PMID:
17881119
12.

Cancer chemoprevention by phytochemicals: potential molecular targets, biomarkers and animal models.

Kwon KH, Barve A, Yu S, Huang MT, Kong AN.

Acta Pharmacol Sin. 2007 Sep;28(9):1409-21. Review.

13.

Adjuvant therapy of colon cancer: current status and future directions.

Chung KY, Saltz LB.

Cancer J. 2007 May-Jun;13(3):192-7. Review.

PMID:
17620769
14.

Inactivation of the candidate tumor suppressor par-4 in endometrial cancer.

Moreno-Bueno G, Fernandez-Marcos PJ, Collado M, Tendero MJ, Rodriguez-Pinilla SM, Garcia-Cao I, Hardisson D, Diaz-Meco MT, Moscat J, Serrano M, Palacios J.

Cancer Res. 2007 Mar 1;67(5):1927-34.

15.

Surgical adjuvant therapy for colorectal cancer: current approaches and future directions.

Monga DK, O'Connell MJ.

Ann Surg Oncol. 2006 Aug;13(8):1021-34. Epub 2006 Jul 29. Review.

PMID:
16897272
16.

The phosphoinositide 3-kinase/Akt1/Par-4 axis: a cancer-selective therapeutic target.

Goswami A, Ranganathan P, Rangnekar VM.

Cancer Res. 2006 Mar 15;66(6):2889-92. Review.

17.

Prostate-apoptosis-response-gene-4 increases sensitivity to TRAIL-induced apoptosis.

Boehrer S, Nowak D, Puccetti E, Ruthardt M, Sattler N, Trepohl B, Schneider B, Hoelzer D, Mitrou PS, Chow KU.

Leuk Res. 2006 May;30(5):597-605. Epub 2006 Mar 2.

PMID:
16513168
18.

Predicting 5-fluorouracil chemosensitivity of liver metastases from colorectal cancer using primary tumor specimens: three-gene expression model predicts clinical response.

Matsuyama R, Togo S, Shimizu D, Momiyama N, Ishikawa T, Ichikawa Y, Endo I, Kunisaki C, Suzuki H, Hayasizaki Y, Shimada H.

Int J Cancer. 2006 Jul 15;119(2):406-13.

19.

Binding and phosphorylation of par-4 by akt is essential for cancer cell survival.

Goswami A, Burikhanov R, de Thonel A, Fujita N, Goswami M, Zhao Y, Eriksson JE, Tsuruo T, Rangnekar VM.

Mol Cell. 2005 Oct 7;20(1):33-44.

20.

Cancer chemoprevention: scientific promise, clinical uncertainty.

Sporn MB, Liby KT.

Nat Clin Pract Oncol. 2005 Oct;2(10):518-25. Review.

PMID:
16205771

Supplemental Content

Support Center